Logo image of KTRA

KINTARA THERAPEUTICS INC (KTRA) Stock Fundamental Analysis

NASDAQ:KTRA - Nasdaq - US49720K2006 - Common Stock - Currency: USD

0.2154  -0.01 (-6.31%)

After market: 0.225 +0.01 (+4.46%)

Fundamental Rating

2

Overall KTRA gets a fundamental rating of 2 out of 10. We evaluated KTRA against 568 industry peers in the Biotechnology industry. While KTRA seems to be doing ok healthwise, there are quite some concerns on its profitability. KTRA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KTRA had negative earnings in the past year.
KTRA had a negative operating cash flow in the past year.
KTRA had negative earnings in each of the past 5 years.
In the past 5 years KTRA always reported negative operating cash flow.
KTRA Yearly Net Income VS EBIT VS OCF VS FCFKTRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

KTRA has a Return On Assets of -137.12%. This is amonst the worse of the industry: KTRA underperforms 84.01% of its industry peers.
KTRA has a Return On Equity of -226.35%. This is in the lower half of the industry: KTRA underperforms 70.69% of its industry peers.
Industry RankSector Rank
ROA -137.12%
ROE -226.35%
ROIC N/A
ROA(3y)-224%
ROA(5y)-257.81%
ROE(3y)-832.26%
ROE(5y)-1280.11%
ROIC(3y)N/A
ROIC(5y)N/A
KTRA Yearly ROA, ROE, ROICKTRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KTRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KTRA Yearly Profit, Operating, Gross MarginsKTRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for KTRA has been increased compared to 1 year ago.
KTRA has more shares outstanding than it did 5 years ago.
KTRA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KTRA Yearly Shares OutstandingKTRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
KTRA Yearly Total Debt VS Total AssetsKTRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -37.01, we must say that KTRA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of KTRA (-37.01) is worse than 91.83% of its industry peers.
There is no outstanding debt for KTRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -37.01
ROIC/WACCN/A
WACCN/A
KTRA Yearly LT Debt VS Equity VS FCFKTRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

A Current Ratio of 2.45 indicates that KTRA has no problem at all paying its short term obligations.
KTRA's Current ratio of 2.45 is on the low side compared to the rest of the industry. KTRA is outperformed by 72.11% of its industry peers.
A Quick Ratio of 2.45 indicates that KTRA has no problem at all paying its short term obligations.
With a Quick ratio value of 2.45, KTRA is not doing good in the industry: 70.87% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 2.45
KTRA Yearly Current Assets VS Current LiabilitesKTRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 77.09% over the past year.
EPS 1Y (TTM)77.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KTRA will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.35% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y17.39%
EPS Next 2Y9.35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KTRA Yearly Revenue VS EstimatesKTRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 20M 40M 60M
KTRA Yearly EPS VS EstimatesKTRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -100 -200 -300 -400

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KTRA. In the last year negative earnings were reported.
Also next year KTRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KTRA Price Earnings VS Forward Price EarningsKTRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KTRA Per share dataKTRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.35%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KTRA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KINTARA THERAPEUTICS INC

NASDAQ:KTRA (10/17/2024, 8:46:26 PM)

After market: 0.225 +0.01 (+4.46%)

0.2154

-0.01 (-6.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-09 2024-10-09/amc
Earnings (Next)11-11 2024-11-11/amc
Inst Owners1.51%
Inst Owner Change0%
Ins Owners5.59%
Ins Owner Change0%
Market Cap11.99M
Analysts43.33
Price Target14.28 (6529.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)-73.53%
DP-0.07%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.19
P/tB 3.19
EV/EBITDA N/A
EPS(TTM)-2.15
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS0
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -137.12%
ROE -226.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-224%
ROA(5y)-257.81%
ROE(3y)-832.26%
ROE(5y)-1280.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.36%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.45
Quick Ratio 2.45
Altman-Z -37.01
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)139.9%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.86%
EPS Next Y17.39%
EPS Next 2Y9.35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y42.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y40.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y39.55%
OCF growth 3YN/A
OCF growth 5YN/A